B+
Bull case
20%
Probability
Target price
$55.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
CNMD
CONMEDCNYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$33.00
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-07
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+48.7
Score
AI commentary
Company-source tone is mixed: stronger underlying Q2 growth and higher adjusted-EPS guidance contrast with near-flat reported sales, a narrower organic-growth range and a tariff-refund benefit. The October 28 announcement creates a defined event window. Post-Q2 price reaction, analyst revisions, and reliable social, options, short-interest and employee measures are unavailable; the zero-valued sentiment fields are placeholders, not observed readings.
RankAlpha Sentiment Codex - 2026-10-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-10-28eventThird-quarter results on October 28Medium impact
CONMED has scheduled its Q3 2026 release and call for October 28. The key test is whether underlying surgical-product growth continues to offset the completed GI product exits. In Q2, reported sales grew 0.3%, versus 6.0% organic constant-currency growth excluding those exits. [#PR-EARNINGS-2026-10-01] [#SEC-8K-2026-07-29] [#8-K-2026-07-29]
2026-12-31catalystDelivery against revised 2026 guidanceMedium impact
After Q2, CONMED raised adjusted diluted EPS guidance from $4.30–$4.45 to $4.48–$4.60, while narrowing organic constant-currency sales-growth guidance from 5.0%–6.5% to 5.0%–6.0%. The next reports will test whether the EPS increase is sustainable: Q2 adjusted EPS included a $0.21 tariff-refund benefit. [#SEC-8K-2026-07-29]
2027-06-30catalystAirSeal robotic compatibility adoptionMedium impact
CONMED announced that AirSeal Robotic Solution is indicated for use with Intuitive's 8 mm hex cannulas on the da Vinci 5 platform. Adoption could support General Surgery growth, but the release provides no uptake or revenue forecast; commercial impact remains unproven. [#SEC-8K-2026-07-29]
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-07 • Updated nightlySource: Internal modelMethodology